July 1, 2008 - Alkermes, Inc. (NASDAQ: ALKS) announced positive preclinical results for three proprietary molecules targeting opioid receptors, including ALKS 33. Data from two preclinical studies demonstrated that the three molecules showed statistically superior oral efficacy as well as evidence for improved metabolic and pharmacokinetic profiles compared to an active control. The data were presented at the 2008 Research Society on Alcoholism/International Society for Biomedical Research on Alcoholism (RSA/ISBRA) Joint Scientific Meeting in Washington, D.C. "We are encouraged by the compelling preclinical profiles emerging for this series of orally active, proprietary molecules, which represent multiple opportunities to advance novel drug candidates into our pipeline," stated Daniel Deaver, Ph.D., vice president, non-clinical development of Alkermes. "These findings support the continued development of next-generation therapeutics to treat a broad range of diseases, including central nervous system disorders and brain reward disorders, such as addiction, obesity and other impulse-control disorders.".. Alkermes' Press Release -
